Replies to post #267094 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"The non-binding term sheet also includes a Right of First Refusal for rights to Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease, such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for rights to Brilacidin in other Gastrointestinal (GI) indications."

Since those Rights are included in a non-binding term sheet (versus a signed definitive agreement), can IPIX currently convey the rights to Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease, such as Ulcerative Colitis and Crohn’s Disease or negotiate the rights to Brilacidin in other Gastrointestinal (GI) indications with other parties?

If the answer is "yes" the rights aren't worth much to the other party at this point, right? If the answer is "no", what kind of compensation do you think IPIX received to provide that exclusivity?

Before you ask, there's no point. It's just a question.